statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today...

KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors

KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVistas board of directors granted nine newly-hired employees inducement options to purchase an...

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) saw unusually-strong trading volume on Thursday . Approximately 1,665,708 shares traded hands during mid-day trading, an increase of...

KalVista Pharmaceuticals (NASDAQ:KALV) Sees Unusually-High Trading Volume

This is a signal that KALV's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...

KalVista Pharmaceuticals (KALV, $11.84) RSI Indicator left the oversold zone on March 28, 2024

KalVista Pharmaceuticals (KALV, $11.13) RSI Indicator left the oversold zone on March 25, 2024

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV  Free Report)  Cantor Fitzgerald cut their FY2025 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a research note issued...

FY2025 EPS Estimates for KalVista Pharmaceuticals, Inc. Cut by Cantor Fitzgerald (NASDAQ:KALV)

KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV  Free Report)  Investment analysts at HC Wainwright issued their Q1 2025 EPS estimates for KalVista Pharmaceuticals in a note issued to...

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Forecasted to Earn Q1 2025 Earnings of ($0.57) Per Share

KalVista Pharmaceuticals Awarded UK Promising Innovative Medicine (PIM) Designation for Sebetralstat

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.

KalVista Pharmaceuticals Inc

Volume	20,051.00
52-Wk High	$16.88
52-Wk Low	$7.21

Current Price	$11.05
Prev Close	$10.78
Open	$11.00
Dividend Yield	0.00%
50-Day Moving Average	$12.34
Beta	0.53
Avg. Volume	632,069.65
PE Ratio	-3.44

52-Week High	$16.88
52-Week Low	$7.21
Market Capitalization	$454.79M
EPS	-$3.14
Price to Book	4.21
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-3.90

KALV KalVista Pharmaceuticals Inc

About

Feed

News

Sentiment

Earnings

Fundamentals